(Q38416523)

2 September 2017

Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease (English)

1 reference

non-alcoholic fatty liver

2 September 2017

1 reference

based on heuristic

inferred from title

metabolic dysfunction–associated steatotic liver disease

1 reference

based on heuristic

inferred from title

author

Sugantha Govindarajan

series ordinal

3

object named as

Sugantha Govindarajan

1 reference

2 September 2017

Michel Henry Mendler

1

1 reference

PubMed ID

15780053

2 September 2017

Gary Kanel

series ordinal

2

1 reference

PubMed ID

15780053

2 September 2017

language of work or name

1 reference

1 April 2005

1 reference

2 September 2017

1 reference

2 September 2017

25

1 reference

2 September 2017

294-304

1 reference

2 September 2017

2

1 reference

Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease

2 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01052.X

Nonalcoholic steatohepatitis: a study of 49 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01052.X

Nonalcoholic fatty liver disease: an agenda for clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01052.X

Defining nonalcoholic fatty liver disease: implications for epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01052.X

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01052.X

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01052.X

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01052.X

21 January 2018

Mallory bodies revisited

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01052.X

Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01052.X

Update on nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01052.X

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01052.X

Diabetes mellitus in patients with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01052.X

Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01052.X

Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01052.X

10.1111/J.1478-3231.2005.01052.X

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference

PubMed ID

15780053